On the other hand, our findings that reducing Vam6 expression in iNKT leads to enhanced iNKT cell function and exhibits augmented anti-tumor efficacy shed light on future gene editing in iNKT cell-based immunotherapy against tumors. The gene discussed is VPS39; the disease is neoplasm.